Mechanizm manipulacji zdrowiem na światową skalę?! Przez to jest tak dużo chorób? Hubert Czerniak

The speaker emphasizes that official RDAs (75–90 mg) prevent scurvy but do not optimize immune function. He cites a mouse study comparing 20 mg/kg vs 200 mg/kg vitamin C for one year: the high-dose group had significantly higher plasma C, larger thymus mass, and elevated splenocytes and thymocytes. He distinguishes that scurvy is the end-stage of collagen failure with tooth loss and systemic infection; high-dose vitamin C maintains supra-physiological collagen quality. Even when tissues appear saturated, bleeding gums may still occur due to niacin deficiency; adding niacin often resolves residual bleeding. His personal experience: 60 g over 9 hours produced no diarrhea, challenging the concept of bowel tolerance as a dose-limiter. He references Linus Pauling’s work and the Ruth Harrell study on Down syndrome children, where gram doses of vitamins (thousands of percent of RDA) improved IQ by up to 5 points and normalized facial features—attempts to refute her work used trivial doses (half a gram of C), underscoring that dose matters.

The speaker devotes a major portion to niacin. He begins with the Grund/Altchul cholesterol discoveries: 2 g niacin lowered total cholesterol by 22% in humans, outperforming any single drug, and slashed triglycerides. He contrasts this with statins’ side-effect profile. He moves to Kaufman’s clinical experience with arthritis—niacinamide plus C, B-complex, A, D3 reversed joint degeneration within 1–2 months, leading Kaufman to declare all joint disease a niacinamide deficiency/dependency. The pelagra–schizophrenia connection is detailed: Goldberger cured pelagra with niacin; the difference between pelagra and schizophrenia was only the speed of response to niacin, implying schizophrenia is a chronic pelagra due to extreme individual niacin requirement. Hoffer cured 60 MS patients with 3–6 g niacin daily, and Klenner used B3 + B-complex + C + E + minerals to treat MS. Additional benefits: pre-treating cells with high-dose niacin before a carcinogen slowed tumor growth by 90%; high-dose niacin with antioxidants lowered cataract incidence by 30–60%; a 2 g dose of niacin stopped cholera-induced diarrhea and diarrhea in pancreatic cancer. The speaker sees niacin as a versatile, cheap, non-toxic therapeutic agent deliberately suppressed by the pharmaceutical industry.

The speaker provides a multi-layered argument. First, epidemiological data: a large cohort study showed strong inverse relationship between 25(OH)D and mortality from all causes, cardiovascular disease, cancer, and respiratory disease, with deficiency (<30 nmol/L ≈ 12 ng/mL) being particularly dangerous. Cedric Garland’s work set the cancer-protective threshold at 60 ng/mL. Yet, many commercial labs set the normal range as 4.8–42.3 ng/mL, which the speaker calls ‘makabrycznie niski’ and dangerous because a young doctor may see a value of 20 ng/mL as normal, ignoring symptoms. He reminisces about pre-1980 textbooks where no toxicity was observed in children at 2,000 IU/kg daily—implying massive safety margin. He contrasts the EU committee’s recommendation of 600 IU/day with their admission that 10,000 IU/day (250 μg) is tolerable, noting the inconsistency. His personal testimony: at 114 ng/mL he felt no drive; at 300–400 ng/mL he had relentless motivation, creativity, needed less sleep, and language learning became ‘like a sponge’. Two anecdotal toxicity cases occurred only at 1.7 million IU/day for months, emphasizing that realistic overdose is nearly impossible. He warns that if the body is toxic with heavy metals or has certain disease processes, serum levels may not reflect tissue sufficiency, and the person may still suffer deficiency symptoms.

The speaker describes a common clinical scenario: a patient with borderline cholesterol, homocysteine of 15 μmol/L, and B12 of 500 pg/mL. Using modern lab norms, everything appears normal; the doctor prescribes a statin. Instead, the speaker advocates recognizing that B12 below 600 is frequently associated with neuropsychiatric symptoms, and that elevated homocysteine is the real culprit driving cholesterol. He notes that cholesterol is not inherently dangerous—it’s an energy shuttle, membrane component, and precursor for steroid hormones and vitamin D. By supplementing B9, B12, and B6, homocysteine normalizes and cholesterol often follows. He adds that about 50% of genetically impaired CBS enzyme cases can be improved with high-dose B6, and that this complexity is ignored by lipid-focused guidelines. The intentional lowering of B12 norms from 300–1200 to 170–600 pg/mL serves to hide deficiency and sell more statins.

This is a brief mention at the end of the niacin discussion. The speaker states that taurine solution applied to the eye influences vision improvement and labels it as interesting to investigate. No studies or further elaboration are provided.

The speaker refers to a historical shift: in the mid-20th century, American flour was fortified with iodine, and breast cancer rates were lower despite high-estrogen contraceptives. A widely taught but unreplicated study—the Wolff–Chaikoff effect—was used to justify removing iodine from food. Instead, bromine was added to flour as a bleaching agent, displacing iodine. He claims that iodine deficiency in utero programs the child for an unnaturally high dopamine requirement, increasing risk of Parkinson’s and MS in adulthood. He also ties low iodine to breast cancer via unopposed estrogen effects. No specific supplementation protocol is given, but the implication is clear: re-establish iodine intake at historical levels and avoid bromine sources.

The speaker frames RDAs as a deliberate under-dosing strategy, comparing them to a minimum wage that ensures mere survival but not well-being. He walks through specific examples: vitamin C RDA of 75–90 mg vs. the grams used by Pauling and himself; niacin RDA of ~15–20 mg vs. 3–6 g used by clinicians; vitamin D RDA of 600–4000 IU vs. the pre-1980 textbook data of 2000 IU/kg in children without toxicity. He claims that after 1980, medical textbooks were purged of these effective-dosing data, and that current lab norms (e.g., vitamin D 4.8–42.3 ng/mL) are set to make people appear normal when they are actually deficient. The continuous push to lower B12 and vitamin D norms further hides widespread insufficiency. The speaker urges listeners to interpret their own lab results against historical and scientific evidence rather than accepting the shifting reference ranges.

The speaker describes his own protocol of taking one flat teaspoon of vitamin C powder (roughly 5 g) in the morning and evening, totaling about 10 g daily. He challenges the concept of bowel tolerance, recounting an experiment where he ingested 60 g over 9 hours (taking a heaping teaspoon every ~40 minutes) during a fever without any diarrhea. He references the work of Linus Pauling and animal research showing that 200 mg/kg improved thymus mass and immune cell counts. For him, scurvy is the endpoint of prolonged deficiency, and the fear of ‘stones’ is unfounded; he encourages others to test high doses themselves. He also notes that even when vitamin C saturation seems adequate, bleeding gums may resolve only after adding niacin, highlighting synergy.

The speaker recounts how U.S. physician Joseph Goldberger cured pelagra with niacin, then notes the diagnostic distinction: if symptoms resolve quickly with niacin, it’s pelagra; if it takes longer, it’s schizophrenia—but both respond to high-dose B3. Abram Hoffer reportedly cured 60 people with multiple sclerosis using 3–6 g niacin daily. William Kaufman used 3–6 g niacinamide plus vitamins C, A, D3, and B-complex to reverse joint degeneration within 1–2 months, claiming all joint disease is essentially a niacinamide deficiency or dependency. The speaker further cites experiments where niacin pre-treatment slowed cancer cell growth by 90% and research showing high-dose niacin with antioxidants reduces cataract risk by 30–60%. Although the RDA for niacin is ~16 mg, these therapeutic protocols use 200–400 times that amount without toxicity concerns—the lethal dose being tens of grams. The mechanism suggested is that some individuals have a genetically high requirement for niacin, and only supraphysiological doses correct the metabolic defect.

The speaker cites a large cohort study where 25(OH)D was inversely related to mortality. He then references the late epidemiologist Cedric Garland, who documented massive associations between low vitamin D and cancers of the colon, prostate, etc., and concluded that the minimum protective level is 60 ng/mL, not 30. The speaker highlights the absurdity of some commercial labs reporting normal ranges as low as 4.8–42.3 ng/mL—levels at which, he argues, nearly everyone is pathologically deficient and serious illness begins below 30. He contrasts this with a pre-1980s textbook stating no toxic effects in children at 2000 IU per kg bodyweight daily, implies that a typical 80–100 kg adult could tolerate extremely high doses without toxicity. He shares his own blood test history where levels around 114 ng/mL left him without drive, whereas 300–400 ng/mL previously gave him enormous motivation, creativity, and accelerated learning ability. Two cases of toxicity occurred only at 1.7 million IU/day for 7 months—a dose he considers unrealistic.

The speaker describes a scenario where a patient has homocysteine of 15 μmol/L (above his preferred limit of 6–8) and B12 of, say, 500 pg/mL. A doctor using current norms sees B12 in range, homocysteine maybe borderline, and elevated cholesterol—so prescribes a statin. If the doctor knew that B12 below 600 is frequently associated with anxiety, depression, or psychosis and that homocysteine drives cholesterol production to repair endothelial damage, he would instead give B12, folate, and B6. The speaker contends that the intentional lowering of norms is part of a larger manipulation to keep people on pharmaceuticals rather than correcting nutritional deficiencies. He also references the enzyme cystathionine beta-synthase, which can be genetically impaired; high-dose B6 can partially compensate, reducing homocysteine by ~50% in some cases. The takeaway: treat B12 deficiency aggressively, aiming for the upper half of the old reference range (600–1200 pg/mL), and always correlate with homocysteine.

The speaker explains that cholesterol is an energy carrier (LDL delivers energy to peripheral cells), a building block for membranes—the ‘brain’ of the cell—and that mitochondrial dysfunction occurs when intracellular milieu is disrupted, leading to cancer (the cell reverts to glycolysis). Therefore, cholesterol should not be feared. He identifies several drivers of elevated cholesterol: (1) heavy metals like lead dissolve in fats; the body synthesizes more cholesterol to sequester these toxins in adipose tissue; (2) carnitine deficiency prevents fatty acid and cholesterol transport into mitochondria for burning, so unused cholesterol accumulates; (3) homocysteine-induced endothelial damage triggers cholesterol as a wound-healing patch. Statins, by inhibiting HMG-CoA reductase (the enzyme also blocked by lead), cause renal failure, heart failure, liver damage, memory disorders, impotence, and increased cancer in animal studies. He notes that a 6-week statin course can produce total memory loss and aggression. No human cancer studies were funded because it’s not in the manufacturer’s interest. Hence, the speaker’s advice: address the underlying nutrient deficiencies rather than taking statins.